RESUMEN
Two cases of infection with Panton-Valentine Leukocidin (PVL) producing strains of Staphylococcus aureus are reported. A 15-year-old insulin dependent diabetic developed toxic shock syndrome and an abscess in the deep tissue around his left hip. A 34-day-old infant presented with a right orbital cellulitis with an intra-orbital collection and septicaemia. In both cases PVL-producing strains of Staphylococcus aureus were isolated. Both surgery and prolonged antibiotic combination regimens were required to eradicate the infection. The cases reported here demonstrate the wide range of clinical presentations seen with PVL producing strains, which have so far been mainly associated with furuncles and necrotising pneumonia.
Asunto(s)
Leucocidinas/metabolismo , Infecciones de los Tejidos Blandos/microbiología , Infecciones Estafilocócicas/diagnóstico , Staphylococcus aureus/metabolismo , Absceso/diagnóstico , Absceso/microbiología , Absceso/terapia , Adolescente , Antibacterianos/uso terapéutico , Toxinas Bacterianas , Celulitis (Flemón)/diagnóstico , Celulitis (Flemón)/microbiología , Exotoxinas , Cadera/patología , Humanos , Recién Nacido , Recien Nacido Prematuro , Imagen por Resonancia Magnética , Masculino , Necrosis/diagnóstico , Necrosis/microbiología , Necrosis/terapia , Enfermedades Orbitales/diagnóstico , Enfermedades Orbitales/microbiología , Enfermedades Orbitales/terapia , Infecciones de los Tejidos Blandos/diagnóstico , Infecciones de los Tejidos Blandos/terapia , Infecciones Estafilocócicas/microbiología , Infecciones Estafilocócicas/terapia , Staphylococcus aureus/aislamiento & purificaciónRESUMEN
Thyrotoxicosis remains a frustrating condition for the young person, family, and health professionals involved. The associated symptoms do not always suggest thyroid disease and patients can be unwell for many months before the diagnosis is made. The antithyroid drug regimen used to treat children and adolescents with thyrotoxicosis varies from one unit to another and yet the potentially life threatening side effects and remission rates post-treatment may be related to the regimen used. Most patients with thyrotoxicosis will need many years of drug therapy if the thyroid gland is not removed surgically or destroyed by radioiodine. Even "definitive" treatment will typically necessitate thyroxine replacement for life.
Asunto(s)
Antitiroideos/uso terapéutico , Tirotoxicosis/terapia , Adolescente , Antitiroideos/efectos adversos , Niño , Humanos , Radioisótopos de Yodo/uso terapéutico , Recurrencia , Crisis Tiroidea/tratamiento farmacológico , Tiroiditis Autoinmune/diagnóstico , Tiroiditis Autoinmune/tratamiento farmacológico , Tiroiditis Autoinmune/terapia , Tirotoxicosis/diagnóstico , Tirotoxicosis/tratamiento farmacológico , Resultado del TratamientoRESUMEN
OBJECTIVE: To compare the prevalence at live birth and the spectrum of cardiovascular malformations in infants born to diabetic mothers with pre-existing diabetes with that in infants of non-diabetic mothers. DESIGN: Prospective study of all live births in the resident population of one health region, with recording of details of the outcome of all pregnancies of women with pre-existing diabetes and of all live born babies with cardiovascular malformations. RESULTS: In the six years 1995-2000 there were 192 618 live births in the study population. Cardiovascular malformations were confirmed in 22 of 609 (3.6%) babies with diabetic mothers and in 1417 of 192 009 (0.74%) babies with non-diabetic mothers. The odds ratio for a cardiovascular malformation with maternal diabetes was 5.0 (95% confidence interval 3.3 to 7.8). Combination of these results with previous reports and comparison with the spectrum of cardiovascular malformations in infants of non-diabetic mothers shows a greater than threefold excess of transposition of the great arteries, truncus arteriosus, and tricuspid atresia. CONCLUSIONS: Pre-existing maternal diabetes is associated with a fivefold increase in risk of cardiovascular malformations. Transposition of the great arteries, truncus arteriosus, and tricuspid atresia are overrepresented to produce a substantial excess of these malformations.
Asunto(s)
Anomalías Cardiovasculares/etiología , Embarazo en Diabéticas , Anomalías Cardiovasculares/epidemiología , Inglaterra/epidemiología , Femenino , Humanos , Lactante , Recién Nacido , Oportunidad Relativa , Embarazo , Embarazo en Diabéticas/epidemiología , Prevalencia , Estudios Prospectivos , Factores de RiesgoRESUMEN
Two novel water-soluble fluorescein myo-inositol phosphate (FLIP) substrates, butyl-FLIP and methyl-FLIP, were used to examine the kinetics and subsite interactions of Bacillus cereus phosphatidylinositol-specific phospholipase C. Butyl-FLIP exhibited sigmoidal kinetics when initial rates are plotted versus substrate concentration. The data fit a Hill coefficient of 1.2-1.5, suggesting an allosteric interaction between two sites. Two substrate molecules bind to this enzyme, one at the active site and one at a subsite, causing an increase in activity. The kinetic behavior is mathematically similar to that of well-known cooperative multimeric enzymes even though this phosphatidylinositol-specific phospholipase C is a small, monomeric enzyme. The less hydrophobic substrate, methyl-FLIP, binds only to the active site and not the activator site, and thus exhibits standard hyperbolic kinetics. An analytical expression is presented that accounts for the kinetics of both substrates in the absence and presence of a nonsubstrate short-chain phospholipid, dihexanoylphosphatidylcholine. The fluorogenic substrates detect activation at much lower concentrations of dihexanoylphosphatidylcholine than previously reported.
Asunto(s)
Fosfatos de Inositol/química , Modelos Químicos , Fosfatidilcolinas/química , Fosfatidilinositol Diacilglicerol-Liasa/química , Espectrometría de Fluorescencia/métodos , Sitio Alostérico , Bacillus cereus/química , Bacillus cereus/enzimología , Sitios de Unión , Simulación por Computador , Activación Enzimática , Fluoresceína , Cinética , Fosfoinositido Fosfolipasa C , Unión Proteica , Especificidad por SustratoRESUMEN
A 3 year old child with Graves' disease and mitral valve prolapse became neutropenic on carbimazole therapy. She was switched to propylthiouracil but the neutropenia recurred. She was treated with radioiodine but required two doses of 113 MBq and then 198 MBq five months later before becoming hypothyroid. The mitral valve prolapse resolved when she was euthyroid on thyroxine replacement. Antithyroid drugs, surgery, and radioiodine all have a place in the management of the thyrotoxic child.
Asunto(s)
Antitiroideos/efectos adversos , Enfermedad de Graves/radioterapia , Radioisótopos de Yodo/uso terapéutico , Neutropenia/inducido químicamente , Carbimazol/efectos adversos , Preescolar , Ecocardiografía , Femenino , Enfermedad de Graves/complicaciones , Humanos , Prolapso de la Válvula Mitral/complicaciones , Propiltiouracilo/efectos adversos , Tirotoxicosis/tratamiento farmacológicoRESUMEN
We describe two brothers with Borjeson-Forssman-Lehmann syndrome and the 22A-->T (Lys8X) PHF6 mutation, who presented with the symptoms and signs of multiple pituitary hormone deficiency. Biochemical investigations and radiology confirmed growth hormone (GH), thyroid stimulating hormone (TSH) and adrenocorticotrophic hormone (ACTH) as well as gonadotrophin deficiency. They were also found to have optic nerve hypoplasia. This family suggests that the BFL gene product may play an important role in midline neuro-development including the hypothalamo-pituitary axis.
Asunto(s)
Anomalías Múltiples/genética , Enfermedades Genéticas Ligadas al Cromosoma X/genética , Hormonas Hipofisarias/deficiencia , Agenesia del Cuerpo Calloso , Codón sin Sentido/genética , Cuerpo Calloso/patología , Criptorquidismo/complicaciones , Criptorquidismo/diagnóstico , Electroforesis en Gel de Poliacrilamida/instrumentación , Electroforesis en Gel de Poliacrilamida/métodos , Anomalías del Ojo/complicaciones , Anomalías del Ojo/diagnóstico , Expresión Génica/genética , Genes Recesivos/genética , Enfermedades Genéticas Ligadas al Cromosoma X/complicaciones , Enfermedades Genéticas Ligadas al Cromosoma X/diagnóstico , Terapia de Reemplazo de Hormonas/métodos , Humanos , Hiperbilirrubinemia/complicaciones , Hiperbilirrubinemia/diagnóstico , Hipoglucemia/complicaciones , Hipoglucemia/diagnóstico , Recién Nacido , Imagen por Resonancia Magnética/métodos , Masculino , Nervio Óptico/anomalías , Fisiognomía , Hipófisis/anomalías , Hipófisis/patología , Hormonas Hipofisarias/genética , Hermanos , SíndromeRESUMEN
The primary objective of this study was to determine the sequence of biochemical signaling events that occur after modulation of the cellular redox state in the B cell lymphoma line, PW, with emphasis on the role of mitochondrial signaling. L-Buthionine sulphoximine (BSO), which inhibits gamma glutamyl cysteine synthetase (gammaGCS), was used to modulate the cellular redox status. The sequence and role of mitochondrial events and downstream apoptotic signals and mediators was studied. After BSO treatment, there was an early decline in cellular glutathione (GSH), followed by an increase in reactive oxygen species (ROS) production, which induced a variety of apoptotic signals (detectable at different time points) in the absence of any external apoptotic stimuli. The sequence of biochemical events accompanying apoptosis included a 95% decrease in total GSH and a partial (25%) preservation of mitochondrial GSH, without a significant increase in ROS production at 24h. Early activation and nuclear translocation of the nuclear factor kappa B subunit Rel A was observed at approximately 3h after BSO treatment. Cytochrome c release into the cytosol was also seen after 24h of BSO treatment. p53 protein expression was unchanged after redox modulation for up to 72 h, and p21waf1 independent loss of cellular proliferation was observed. Surprisingly, a truncated form of p53 was expressed in a time-dependent manner, beginning at 24h after BSO incubation. Irreversible commitment to apoptosis occurred between 48 and 72 h after BSO treatment when mitochondrial GSH was depleted, and there was an increase in ROS production. Procaspase 3 protein levels showed a time-dependent reduction following incubation with BSO, notably after 48 h, that corresponded with increasing ROS levels. At 96 h, caspase 3 cleavage products were detectable. The pan-caspase inhibitor zVADfmk, partially blocked the induction of apoptosis at 48 h, and was ineffective after 72 h. PW cells could be rescued from apoptosis by removing them from BSO after up to 48, but not 72 h incubation with BSO. Mitochondrial transmembrane potential (DeltaPsi(m)) remained intact in most of the cells during the 72 h observation period, indicating that DeltaPsi(m) dissipation is not an early signal for the induction of redox dependent apoptosis in PW cells. These data suggest that a decrease in GSH alone can act as a potent early activator of apoptotic signaling. Increased ROS production following mitochondrial GSH depletion, represents a crucial event, which irreversibly commits PW cells to apoptosis.
Asunto(s)
Apoptosis/fisiología , Butionina Sulfoximina/farmacología , Glutatión/metabolismo , Mitocondrias/metabolismo , Especies Reactivas de Oxígeno/metabolismo , Antimetabolitos Antineoplásicos/farmacología , Apoptosis/efectos de los fármacos , Ciclo Celular/efectos de los fármacos , Grupo Citocromo c/metabolismo , Citosol/metabolismo , Ditiotreitol/farmacología , Glutatión/deficiencia , Humanos , Linfoma de Células B/metabolismo , Linfoma de Células B/patología , Potenciales de la Membrana/efectos de los fármacos , Potenciales de la Membrana/fisiología , Mitocondrias/fisiología , FN-kappa B/metabolismo , Transporte de Proteínas/efectos de los fármacos , Transporte de Proteínas/fisiología , Transducción de Señal/fisiología , Factor de Transcripción ReIA , Células Tumorales Cultivadas , Proteína p53 Supresora de Tumor/biosíntesisRESUMEN
The recent completion of the deletion of essentially all of the ORFs in yeast is an important new resource for identifying the phenotypes of unknown genes. Each ORF is replaced with a cassette containing unique tag sequences that allow rapid parallel analysis of strains in a pool by using hybridization to a high-density oligonucleotide array. We examined the utility of this system to identify genes conferring resistance to UV irradiation by using a pool of 4,627 individual homozygous deletion strains (representing deletions of all nonessential genes). We identified most of the nonessential genes previously shown to be involved in nucleotide excision repair, in cell cycle checkpoints, in homologous recombination, and in postreplication repair after UV damage. We also identified and individually confirmed, by replacing the genes, three new genes, to our knowledge not previously reported to confer UV sensitivity when deleted. Two of these newly identified genes have human orthologs associated with cancer, demonstrating the potential of this system to uncover human genes affecting sensitivity to DNA-damaging agents and genes potentially involved in cancer formation.
Asunto(s)
Tolerancia a Radiación , Saccharomyces cerevisiae/genética , Saccharomyces cerevisiae/efectos de la radiación , Daño del ADN , Análisis de Secuencia por Matrices de Oligonucleótidos , Sistemas de Lectura Abierta , Rayos UltravioletaRESUMEN
A non-radioactive micro-assay for the cyclic phosphodiesterase reaction catalyzed by Bacillus cereus phosphatidylinositol-specific phospholipase C is described. The assay involves high-performance thin-layer chromatography on silica gel to resolve the substrate (myo-inositol 1,2-cyclic phosphate) and the product (myo-inositol 1-phosphate), followed by detection with a lead tetraacetate-fluorescein stain. The quantitation of these inositol phosphates in sample spots relative to a series of standards is accomplished by analysis of the fluorescent plate image with a commercial phosphoimager and associated software. The experimental considerations for reliable quantitation of inositol monophosphates in the range of 0.1 to 50 nmol are presented.
Asunto(s)
Cromatografía en Capa Delgada/métodos , Fosfatos de Inositol/análisis , Bacillus cereus/enzimología , Fosfatidilinositol Diacilglicerol-Liasa , Fosfoinositido Fosfolipasa C , Sensibilidad y Especificidad , Espectrometría de Fluorescencia , Fosfolipasas de Tipo C/metabolismoRESUMEN
An improved synthesis of fluorogenic substrate analogues for phosphatidylinositol-specific phospholipase C (PI-PLC) is described. The water-soluble substrates, which are derived from fluorescein, are not fluorescent until cleaved by the enzyme, and provide a convenient means to continuously monitor PI-PLC activity. The improvement in the synthesis lies in the method used to protect the hydroxyl groups of the inositol portion of the substrate molecule and allows a milder deprotection procedure to be used. The result is a much more reproducible synthesis of the substrate. The improved procedure has been employed to synthesize a series of fluorogenic substrates, which differ in the length of the aliphatic tail attached to the fluorescein portion of the molecule. The length of the tail was found to have a significant effect on the rate of cleavage of these substrates.
Asunto(s)
Fluoresceína/química , Colorantes Fluorescentes/síntesis química , Fosfolipasas de Tipo C/metabolismo , Fluoresceína/metabolismo , Colorantes Fluorescentes/química , Colorantes Fluorescentes/metabolismo , Estructura Molecular , Fosfatidilinositol Diacilglicerol-Liasa , Fosfoinositido Fosfolipasa CRESUMEN
The cell--cell adhesion molecule 1 (C-CAM1) plays an important role as a tumor suppressor for prostate cancer. Decreased expression of C-CAM1 was detected in prostate, breast, and colon carcinoma. Reexpression of C-CAM1 in prostate and breast cancer cell lines was able to suppress tumorigenicity in vivo. These observations suggest that C-CAM1 may be used as a marker for cancer detection or diagnosis. To generate monoclonal antibodies specific to C-CAM1, we have overexpressed full-length human C-CAM1 in Sf9 cells using a baculovirus expression system. The protein was purified 104-fold using nickel affinity chromatography. About 0.4 mg purified C-CAM1 was obtained from 200 mg of infected cells. When the purified protein was digested with peptidyl-N-glycosidase, the apparent mobility of the protein on SDS--PAGE changed from 90 to 58 kDa, which is close to the molecular weight predicted from the cloned cDNA sequence. This observation suggests that C-CAM1 was glycosylated on asparagine residues when expressed in Sf9 cells. Western blotting and internal protein sequencing analysis confirmed that the purified protein is human C-CAM1. Biochemical and functional assays indicate that this protein expressed in Sf9 cells displays characteristics similar to those of native protein, including adhesion function and glycosylation modification. Using this protocol, sufficient quantity of this protein can be produced with purity suitable for monoclonal antibody generation and biochemical study.
Asunto(s)
Adenosina Trifosfatasas/aislamiento & purificación , Adenosina Trifosfatasas/metabolismo , Moléculas de Adhesión Celular/aislamiento & purificación , Moléculas de Adhesión Celular/metabolismo , Spodoptera , Adenosina Trifosfatasas/química , Adenosina Trifosfatasas/genética , Amidohidrolasas/metabolismo , Secuencia de Aminoácidos , Animales , Antígenos CD , Baculoviridae/genética , Western Blotting , Adhesión Celular , Moléculas de Adhesión Celular/química , Moléculas de Adhesión Celular/genética , Línea Celular , Tamaño de la Célula , Cromatografía de Afinidad , Glicosilación , Humanos , Níquel/metabolismo , Péptido-N4-(N-acetil-beta-glucosaminil) Asparagina Amidasa , Proteínas Recombinantes/química , Proteínas Recombinantes/aislamiento & purificación , Proteínas Recombinantes/metabolismo , Análisis de Secuencia de Proteína , Spodoptera/citología , Spodoptera/metabolismo , Spodoptera/virologíaRESUMEN
Tirapazamine (TPZ) is a bioreductive drug that exhibits a high degree of selective toxicity toward hypoxic cells, and at doses that are used clinically, little or no cell killing is observed in aerobic cells. Nonetheless, the effects of TPZ on aerobic tissues are still responsible for the dose limitations on the clinical administration of this drug. Clinical side effects include fatigue, muscle cramping, and reversible ototoxicity. We have investigated TPZ-induced changes in the mitochondria in aerobically exposed cells as a potential mediator of these side effects. Our data show that aerobic administration of TPZ at clinically relevant doses results in a profound loss in the mitochondrial membrane potential (MMP). We show that loss in the MMP occurs in a variety of cell lines in vitro and also occurs in muscle tissues in vivo. The loss in MMP is temporary because recovery occurs within 2 h. TPZ is directly metabolized within mitochondria to a DNA-damaging form, and this metabolism leads to both the cell-killing effects of TPZ on aerobic cells at high doses and to the loss in MMP at clinically relevant doses. Using cell lines derived from genetically modified mice with a targeted deletion in manganese superoxide dismutase, we have further distinguished the phenotypic effects of TPZ in mitochondria at high toxic doses versus those at clinically relevant doses. We have investigated several potential mechanisms for this TPZ-induced loss in MMP. Our results indicate no change in the rate of cellular respiration in TPZ-treated cells. This implies that the loss in MMP results from an inability of the inner mitochondrial membrane to sustain a potential across the membrane after TPZ treatment. Incubation of cells with an inhibitor of the mitochondrial permeability transition suggests that the loss of MMP may result from the regulated opening of a large mitochondria channel.
Asunto(s)
Antineoplásicos/toxicidad , Mitocondrias/efectos de los fármacos , Oxígeno/metabolismo , Triazinas/toxicidad , Aerobiosis , Animales , Antineoplásicos/metabolismo , Células CHO/efectos de los fármacos , Permeabilidad de la Membrana Celular/efectos de los fármacos , Permeabilidad de la Membrana Celular/fisiología , Cricetinae , Cruzamientos Genéticos , Transporte de Electrón/fisiología , Humanos , Membranas Intracelulares/efectos de los fármacos , Membranas Intracelulares/fisiología , Potenciales de la Membrana/efectos de los fármacos , Ratones , Ratones Endogámicos BALB C , Ratones Noqueados , Mitocondrias/metabolismo , Mitocondrias/fisiología , Mitocondrias Musculares/efectos de los fármacos , Mitocondrias Musculares/metabolismo , Mitocondrias Musculares/fisiología , Superóxido Dismutasa/genética , Superóxido Dismutasa/metabolismo , Superóxidos/metabolismo , Tirapazamina , Triazinas/metabolismo , Células Tumorales CultivadasRESUMEN
PURPOSE: To determine if the observed tirapazamine (TPZ)-cisplatin synergistic cell kill was mediated at the cellular level by impairment of upregulation of key proteins involved in repair of DNA interstrand crosslinks. Cisplatin sensitivity has been shown to be dependent on the expression of the two DNA repair proteins ERCC1 and XPA. ERCC1 expression has also been shown to be upregulated by cisplatin exposure. Therefore, these studies were undertaken to determine if hypoxia-activated TPZ pretreatment inhibited the cells' normal protective response to cisplatin via inhibiting the upregulation of ERCC1 and/or XPA expression. METHODS AND MATERIALS: Two different cell lines, one cisplatin sensitive and one cisplatin resistant, were treated with TPZ, cisplatin, both drugs together (which results in additive cytotoxicity), or TPZ followed by cisplatin (which results in synergistic cytotoxicity). All cells were exposed to 1 h of hypoxia to bioactivate the TPZ. Expression of ERCC1 and XPA were evaluated at the mRNA and protein level at 24 or 48 h after drug exposure. RESULTS: In the cisplatin-sensitive non-small-cell lung cancer cell line, ERCC1 expression at the mRNA or protein level was not significantly altered in any of the treatment groups. In the cisplatin-resistant ovarian cancer cell line, ERCC1 expression was upregulated by TPZ, but not by cisplatin alone. The change in protein expression was less pronounced than the change in mRNA level. XPA expression was not significantly changed from baseline in either cell line at the mRNA or protein level. CONCLUSION: In contrast to reports in the literature, this study did not demonstrate cisplatin inducing its own repair by upregulating the DNA crosslink repair proteins ERCC1 or XPA. Therefore, the TPZ-cisplatin synergism cannot be mediated through hypoxia-activated TPZ inhibiting this cellular protective response. TPZ alone, however, was able to alter repair protein expression, which may play a role in mediating its cytotoxicity.
Asunto(s)
Antineoplásicos/farmacología , Cisplatino/farmacología , Reparación del ADN/fisiología , Proteínas de Unión al ADN/efectos de los fármacos , Endonucleasas , Proteínas/efectos de los fármacos , Fármacos Sensibilizantes a Radiaciones/farmacología , Triazinas/farmacología , Hipoxia de la Célula/fisiología , Proteínas de Unión al ADN/metabolismo , Sinergismo Farmacológico , Humanos , Proteínas/metabolismo , ARN Mensajero/metabolismo , Tirapazamina , Células Tumorales Cultivadas/efectos de los fármacos , Regulación hacia Arriba/efectos de los fármacos , Proteína de la Xerodermia Pigmentosa del Grupo ARESUMEN
Mutations in ATM, the gene defective in the human genetic disorder ataxia-telangiectasia (A-T), have been described in A-T patients and in a variety of tumor samples. Most of these arise due to exon skipping. We developed an RT-PCR based protein truncation test (PTT) to screen for ATM mutations in breast cancer patients showing adverse response to radiotherapy. An additional PTT product was evident in the ATM gene in peripheral blood mononuclear cells (PBMCs) from blood samples that were collected 2 days or more prior to RNA extraction. Lymphoblastoid cell lines established from the same blood samples showed no evidence of the additional band. Cloning and sequencing of the additional RT-PCR product revealed an exact deletion of exon 20 (2639 del 200), pointing to exon skipping. RT-PCR analysis of RNA extracted from freshly prepared PBMCs from 3 normal individuals showed no evidence of the additional RT-PCR product but when the blood was stored for 2-3 days prior to RNA extraction the lower molecular weight band was evident in every sample. DNA sequencing confirmed this to be due to loss of exon 20. These data suggest that mRNA-based mutation analysis on ATM should be carried out on unstored blood samples to avoid artificial loss of exons that give rise to apparent mutations.
Asunto(s)
Ataxia Telangiectasia/genética , Conservación de la Sangre/métodos , Exones/genética , Proteínas Serina-Treonina Quinasas/genética , Reacción en Cadena de la Polimerasa de Transcriptasa Inversa , Eliminación de Secuencia , Empalme Alternativo , Proteínas de la Ataxia Telangiectasia Mutada , Neoplasias de la Mama/sangre , Neoplasias de la Mama/genética , Neoplasias de la Mama/radioterapia , Proteínas de Ciclo Celular , Línea Celular Transformada , Análisis Mutacional de ADN , Proteínas de Unión al ADN , Humanos , Proteínas Serina-Treonina Quinasas/sangre , Transcripción Genética , Proteínas Supresoras de TumorRESUMEN
PURPOSE: The dose intensity of radiotherapy (RT) used in cancer treatment is limited in rare individuals who display severe normal tissue reactions after standard RT treatments. Novel predictive assays are required to identify these individuals prior to treatment. The mechanisms responsible for such reactions are unknown, but may involve dysfunction of genes involved in the sensing and response of cells to DNA damage. The breast cancer susceptibility genes BRCA1 and BRCA2 are implicated in DNA damage repair and the control of genome stability. The purpose of this study was to determine if clinical radiation hypersensitivity is related to mutations of the BRCA1 and BRCA2 genes. Such information is of potential use in the clinical management of BRCA mutation carriers and their families. METHODS AND MATERIALS: Twenty-two cancer patients who developed severe normal tissue reactions after RT were screened for mutations of BRCA1 and BRCA2, using various methods including protein truncation testing, direct DNA sequencing, and a PCR-based BRCA1 exon 13 duplication test. RESULTS: No mutations were detected in the 22 patients tested, despite screening for the majority of commonly described types of mutations of BRCA1 and BRCA2. CONCLUSION: These early results suggest that genes other than BRCA1 and BRCA2 probably account for most cases of clinical radiation hypersensitivity, and that screening for mutations of BRCA1 and BRCA2 is unlikely to be useful in predicting response to radiotherapy. However, it has not been excluded that some BRCA1 or BRCA2 heterozygotes might experience unexpected RT toxicity; further BRCA mutation screening on radiation sensitive individuals is warranted.
Asunto(s)
Neoplasias de la Mama/genética , Genes BRCA1/genética , Predisposición Genética a la Enfermedad/genética , Mutación , Proteínas de Neoplasias/genética , Factores de Transcripción/genética , Proteína BRCA2 , Neoplasias de la Mama/radioterapia , Análisis Mutacional de ADN/métodos , Femenino , Humanos , Tolerancia a Radiación/genéticaRESUMEN
We assessed whether a 1-year teaching programme in northern Zanzibar would improve prescribing practice. Data on polypharmacy and appropriateness of the treatment of upper-respiratory infection, anaemia, and scabies from the 17 primary health-care units in northern Zanzibar were analysed before and after the teaching programme. There was a significant and sustained reduction in polypharmacy and an improvement in the treatment of upper-respiratory infection, scabies, and anaemia. This teaching programme has been successful in improving prescribing practices in a less-developed country.
Asunto(s)
Atención Primaria de Salud/normas , Anemia/tratamiento farmacológico , Prescripciones de Medicamentos/normas , Prescripciones de Medicamentos/estadística & datos numéricos , Educación Profesional , Humanos , Evaluación de Programas y Proyectos de Salud , Infecciones del Sistema Respiratorio/tratamiento farmacológico , Escabiosis/tratamiento farmacológico , TanzaníaRESUMEN
AIMS: To establish the extent and type of premedication used before intubation in neonatal units in the United Kingdom. METHODS: A structured telephone survey was conducted of 241 eligible units. Units were subdivided into those that routinely intubated and ventilated babies (routine group) and those that transferred intubated and ventilated babies (transfer group). RESULTS: Of the units contacted, 239 (99%) participated. Only 88/239 (37%) gave any sedation before intubating on the unit and only 34/239 (14%) had a written policy covering this. Morphine was used most commonly (66%), with other opioids and benzodiazepines used less frequently. Of the 88 units using sedation, 19 (22%) also used paralysis. Suxamethonium was given by 10/19 (53%) but only half of these combined it with atropine. Drug doses varied by factors of up to 200, even for commonly used drugs. CONCLUSION: Most UK neonatal units do not sedate babies before intubating, despite evidence of physiological and practical benefits. Only a minority have written guidelines, which prohibits auditing of practice.
Asunto(s)
Hipnóticos y Sedantes/administración & dosificación , Cuidado Intensivo Neonatal/estadística & datos numéricos , Intubación Intratraqueal/estadística & datos numéricos , Premedicación/estadística & datos numéricos , Ansiolíticos/administración & dosificación , Atropina/administración & dosificación , Benzodiazepinas , Humanos , Recién Nacido , Cuidado Intensivo Neonatal/organización & administración , Morfina/administración & dosificación , Narcóticos/administración & dosificación , Bloqueo Neuromuscular , Fármacos Neuromusculares Despolarizantes/administración & dosificación , Política Organizacional , Parasimpatolíticos/administración & dosificación , Transferencia de Pacientes/estadística & datos numéricos , Guías de Práctica Clínica como Asunto , Respiración Artificial/estadística & datos numéricos , Succinilcolina/administración & dosificación , Reino Unido/epidemiologíaRESUMEN
The gene mutated in the human genetic disorder ataxia-telangiectasia codes for a protein, ATM, the known functions of which include response to DNA damage, cell cycle control, and meiotic recombination. Consistent with these functions, ATM is predominantly present in the nucleus of proliferating cells; however, a significant proportion of the protein has also been detected outside the nucleus in cytoplasmic vesicles. To understand the possible role of extra-nuclear ATM, we initially investigated the nature of these vesicles. In this report we demonstrate that a portion of ATM co-localizes with catalase, that ATM is present in purified mouse peroxisomes, and that there are reduced levels of ATM in the post-mitochondrial membrane fraction of cells from a patient with a peroxisome biogenesis disorder. Furthermore the use of the yeast two-hybrid system demonstrated that ATM interacts directly with a protein involved in the import of proteins into the peroxisome matrix. Because peroxisomes are major sites of oxidative metabolism, we investigated catalase activity and lipid hydroperoxide levels in normal and A-T fibroblasts. Significantly decreased catalase activity and increased lipid peroxidation was observed in several A-T cell lines. The localization of ATM to peroxisomes may contribute to the pleiotropic nature of A-T.
Asunto(s)
Peroxisomas/química , Proteínas Serina-Treonina Quinasas/análisis , Secuencia de Aminoácidos , Animales , Ataxia Telangiectasia/enzimología , Ataxia Telangiectasia/metabolismo , Ataxia Telangiectasia/patología , Proteínas de la Ataxia Telangiectasia Mutada , Catalasa/análisis , Catalasa/genética , Catalasa/metabolismo , Proteínas de Ciclo Celular , Línea Celular , Núcleo Celular/química , Proteínas de Unión al ADN , Fibroblastos/química , Fibroblastos/citología , Fibroblastos/metabolismo , Humanos , Inmunohistoquímica , Peróxidos Lipídicos/metabolismo , Masculino , Ratones , Datos de Secuencia Molecular , Trastorno Peroxisomal/metabolismo , Trastorno Peroxisomal/patología , Proteínas Serina-Treonina Quinasas/genética , Proteínas Serina-Treonina Quinasas/metabolismo , Proteínas Recombinantes de Fusión/análisis , Proteínas Recombinantes de Fusión/genética , Proteínas Recombinantes de Fusión/metabolismo , Alineación de Secuencia , Proteínas Supresoras de Tumor , Técnicas del Sistema de Dos HíbridosRESUMEN
Loss of heterozygosity (LOH) involving the distal part of the short arm of chromosome 1 occurs frequently in ovarian adenocarcinomas but the tumour suppressor gene(s) targeted by this event is unknown. We have used five microsatellite markers in a panel of 56 ovarian adenocarcinomas to determine which part of 1p34 - 36 is the focus of this LOH. LOH was considerably more common at 1p36 (43%) than at 1p34 - 35 (18%), and 11 tumours showed LOH at 1p36 but not at 1p34 - 35. These data strongly suggest the presence of a tumour suppressor gene inactivated in ovarian adenocarcinoma at 1p36. The p53 homologue, p73, has recently been isolated and mapped to 1p36 and therefore is a candidate for this tumour suppressor gene. However, RT - PCR and Western analyses revealed strong expression of p73 in ovarian adenocarcinoma cell lines but very low or undetectable levels in normal ovarian surface epithelial cells. Immunohistochemical analysis of primary ovarian tumours showed that only 3/22 (14%) contained p73 expressing cells. There was no association between 1p36 LOH and p73 expression in ovarian tumours, nor between p73 and p53 expression. These findings strongly suggest that p73 is not the target of 1p36 LOH in ovarian adenocarcinomas but indicate the presence of an, as yet unidentified, tumour suppressor gene in this region that plays an important role in ovarian tumorigenesis.
Asunto(s)
Adenocarcinoma/genética , Cromosomas Humanos Par 1 , Proteínas de Unión al ADN/genética , Genes Supresores de Tumor , Pérdida de Heterocigocidad , Proteínas Nucleares/genética , Neoplasias Ováricas/genética , Adenocarcinoma/metabolismo , Adenocarcinoma/patología , Proteínas de Unión al ADN/biosíntesis , Femenino , Humanos , Proteínas Nucleares/biosíntesis , Neoplasias Ováricas/metabolismo , Neoplasias Ováricas/patología , Células Tumorales Cultivadas , Proteína Tumoral p73 , Proteínas Supresoras de TumorRESUMEN
Patients with the human genetic disorder ataxia-telangiectasia (A-T) are characterized by immunodeficiency and a predisposition to develop lymphoid malignancies. The gene mutated in A-T patients, ATM, codes for a high molecular weight protein that is implicated in DNA damage recognition and cell cycle control. The ATM protein does not change in amount or cellular distribution throughout the cell cycle or in response to DNA damaging agents. Because peripheral blood mononuclear cells (PBMCs) are largely in a state of quiescence and can be readily stimulated to enter a proliferative phase and because A-T cells exhibit growth abnormalities and senescence, indicative of a general intracellular defect in signalling, we chose PBMCs to examine the relationship of ATM to the proliferative status of the cell. We show here that ATM protein is present at low levels in freshly isolated PBMCs and increases approximately 6-fold to 10-fold in response to a mitogenic stimulus, reaching a maximum after 3 to 4 days. A similar, but delayed response, was evident in the presence of serum only. This increase in ATM protein was accompanied by an increase in ATM kinase activity. While expression of ATM protein increased during proliferation, ATM mRNA expression was unchanged in stimulated and unstimulated cells and there was no evidence for increased ATM protein stability in the phytohemagglutinin (PHA)-treated cells. In keeping with the reduced levels of ATM in quiescent cells, the extent of radiation-induction of the p53 pathway was significantly lower than in mitogen-stimulated cells. Basal levels of p21 were elevated in quiescent cells, and the response to radiation was negligible or reduced compared with proliferating cells over a 2-hour period. Overall, the data suggest that the increase in ATM protein in proliferating cells is due to posttranscriptional regulation and points to a role for ATM in more general signalling.